

Ohr Pharmaceutical Inc  
Form NT 10-K  
December 15, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

SEC FILE  
NUMBER

333-88480

CUSIP  
NOTIFICATIONNUMBER

**OF LATE FILING**

67778H200

(Check one) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR

Form

N-CSR

For

Period September 30, 2014

Ended:

Transition Report on Form 10-K

Transition Report on Form 20-F

Transition Report on Form 11-K

Transition Report on Form 10-Q

Transition Report on Form N-SAR

For the

Transition

Period

Ended:

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above,  
identify the Item(s) to which the notification relates:

**PART I – REGISTRANT INFORMATION**

Ohr Pharmaceutical, Inc.  
Full Name of Registrant

Former Name if Applicable

800 3rd Avenue, 11th Floor,  
Address of Principal Executive Office (*Street and Number*)

New York, NY 10022  
City, State and Zip Code

**PART II – RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or  
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the  
following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form  
could not be eliminated without unreasonable effort or expense  
The subject annual report, semi-annual report, transition report on  
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form  
N-CSR, or portion thereof, will be filed on or before the fifteenth  
calendar day following the prescribed due date; or the subject
- (b) quarterly report or transition report on Form 10-Q or subject  
distribution report on Form 10-D, or portion thereof, will be filed  
on or before the fifth calendar day following the prescribed due  
date; and
- (c) The accountant's statement or other exhibit required by Rule  
12b-25(c) has been attached if applicable.

### PART III - NARRATIVE

The Registrant's Annual Report on Form 10-K could not be filed within the prescribed time period due to delays, which could not be eliminated without unreasonable effort or expense, associated with preparation of the Registrant's financial statements. The Registrant anticipates filing its Form 10-K within the fifteen calendar day extension period provided under Rule 12b-25.

### PART IV – OTHER INFORMATION

Name and telephone number of  
(1) person to contact in regard to  
this notification  
Sam  
Backenroth 682-3545  
CFO  
(Name) (Area Code) (Telephone  
Number)

Have all other periodic reports  
required under Section 13 or 15(d)  
of the Securities Exchange Act of  
1934 or Section 30 of the  
Investment Company Act of 1940  
(2) during the preceding 12 months or  
for such shorter period that the  
registrant was required to file such  
report(s) been filed? If answer is  
no, identify  
report(s). Yes No

Is it anticipated that any  
significant change in results of  
operations from the corresponding  
(3) period for the last fiscal year will  
be reflected by the earnings  
statements to be included in the  
subject report or portion thereof?  
Yes No

If so, attach an explanation of the  
anticipated change, both  
narratively and quantitatively, and,  
if appropriate, state the reasons  
why a reasonable estimate of the  
results cannot be made.

For the fiscal year ended September 30, 2014, the Company had zero revenues and operating expenses of approximately \$9.1 million for losses of approximately \$9.1 million, as compared to zero revenues and operating expenses of \$4,620,916 for losses of \$5,652,488 for the fiscal year ended September 30, 2013. The increased losses and expenses resulted from an increase in development activity, including clinical and preclinical studies.

**Ohr Pharmaceutical, Inc.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2014 By: /s/ Sam Backenroth  
Sam Backenroth,  
Chief Financial  
Officer  
(Principal  
accounting and  
financial officer)